Oramed Pharmaceuticals Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Oramed Pharmaceuticals stock.
View analyst ratings for Oramed Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Oramed Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Oramed Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Oramed Pharmaceuticals saw a decrease in short interest during the month of August. As of August 13th, there was short interest totaling 1,380,000 shares, a decrease of 27.7% from the July 29th total of 1,910,000 shares. Based on an average daily volume of 758,400 shares, the short-interest ratio is presently 1.8 days. Currently, 4.9% of the shares of the company are short sold.
View Oramed Pharmaceuticals' Short Interest.

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, November 23rd 2021.
View our earnings forecast for Oramed Pharmaceuticals.

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its earnings results on Tuesday, July, 13th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.20) by $0.03. The biotechnology company earned $0.68 million during the quarter, compared to analyst estimates of $0.70 million. Oramed Pharmaceuticals had a negative net margin of 680.53% and a negative trailing twelve-month return on equity of 40.91%.
View Oramed Pharmaceuticals' earnings history.

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, ORMP shares have increased by 530.5% and is now trading at $20.87.
View which stocks have been most impacted by COVID-19.

4 equities research analysts have issued 12-month price targets for Oramed Pharmaceuticals' shares. Their forecasts range from $20.00 to $30.00. On average, they expect Oramed Pharmaceuticals' stock price to reach $25.00 in the next year. This suggests a possible upside of 19.8% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Some companies that are related to Oramed Pharmaceuticals include Agios Pharmaceuticals (AGIO), Prestige Consumer Healthcare (PBH), Sage Therapeutics (SAGE), OPKO Health (OPK), ACADIA Pharmaceuticals (ACAD), Taro Pharmaceutical Industries (TARO), Erasca (ERAS), Aurinia Pharmaceuticals (AUPH), Pacira BioSciences (PCRX), Morphic (MORF), Corcept Therapeutics (CORT), Arcus Biosciences (RCUS), ATA (ATAI), IGM Biosciences (IGMS) and Ligand Pharmaceuticals (LGND).
View all of ORMP's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

Oramed Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include BlackRock Inc. (3.90%), State Street Corp (1.08%), Geode Capital Management LLC (0.67%), Northern Trust Corp (0.65%), Millennium Management LLC (0.62%) and Vanguard Group Inc. (0.38%).
View institutional ownership trends for Oramed Pharmaceuticals.

ORMP stock was sold by a variety of institutional investors in the last quarter, including Citadel Advisors LLC, Susquehanna International Group LLP, Close Asset Management Ltd, Oppenheimer & Co. Inc., and Citigroup Inc..
View insider buying and selling activity for Oramed Pharmaceuticals or view top insider-selling stocks.

ORMP stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., State Street Corp, Northern Trust Corp, Geode Capital Management LLC, Vanguard Group Inc., Nuveen Asset Management LLC, Morgan Stanley, and Morgan Stanley.
View insider buying and selling activity for Oramed Pharmaceuticals or or view top insider-buying stocks.

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ORMP stock can currently be purchased for approximately $20.87.

Oramed Pharmaceuticals has a market capitalization of $678.57 million and generates $2.71 million in revenue each year. The biotechnology company earns $-11,510,000.00 in net income (profit) each year or ($0.56) on an earnings per share basis.

Oramed Pharmaceuticals employs 12 workers across the globe.

The official website for Oramed Pharmaceuticals is www.oramed.com.

Oramed Pharmaceuticals is headquartered at 1185 AVENUE SUITE 228, NEW YORK NY, 10036.

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at (844) 967-2633 or via email at [email protected]